Cosentyx
NICE green-light for Novartis skin drug
May 29, 2015Sales and Marketing Cosentyx, IL-17, NICE, Novartis, Secukinumab
NICE has released positive draft guidance for three treatments, including the first in a new generation of psoriasis drugs. Novartis’ …
Novartis and Abbott start year with strong Q1 sales
April 23, 2015Sales and Marketing Abbott, Amgen, Cosentyx, GSK, Neupogen, Novartis, Secukinumab, Zarxio, biosimilar, filgrastim, financials
Novartis and Abbott have both posted strong first-quarter results and made bullish predictions about their financial performance in 2015. Novartis …
Pfizer, Novartis and Celgene among late-stage psoriasis trial advances
March 23, 2015Sales and Marketing Celgene, Cosentyx, Enbrel, FDA, Novartis, Pfizer, otezla, psoriasis, tofacitinib
Pfizer bosses say they are confident of a positive FDA application for tofacitinib after announcing positive Phase III study results. …
Novartis gets FDA approval for psoriasis drug
January 22, 2015Sales and Marketing Cosentyx, European Commission, FDA, Novartis, Secukinumab, psoriasis
The US Food and Drug Administration (FDA) has shown Novartis’ skin condition drug Cosentyx the green light to treat patients …
Latest content
Five Facts about cardiovascular disease
August 9, 2026
